Novartis Acquires Myricx Bio in $1.5 Billion Deal
Pharmaceutical giant Novartis has announced its acquisition of UK biotech company Myricx Bio, a specialist in cancer medications, for $1.5 billion. The deal aims to bolster Novartis's cancer research portfolio.